N/A N=1,000 Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil
Malaria Diagnosis
Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Malaria · Severe Malaria
Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05
Phase 1 N=32 Trial to Evaluate L9LS in Healthy Adults
Malaria
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of L9LS Product Administration — 2; 3; 3; 4 Participants
Phase 3 N=579 Chemopreventive Therapy for Malaria in Ugandan Children
Malaria
Primary: Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants — 6.95; 6.73; 5.21; 3.02 Episode per person year at risk — p=0.57
Phase 2 N=214 Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs). — 17; 17 subjects
Phase 1 N=2 Dose Escalation PfSPZ-CVac
Malaria
Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants
Phase 1 N=30 Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria
Primary: Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period — 10; 10; 9; 10 participants
Phase 3 N=176 HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
Malaria · HIV Infections
Primary: Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk. — 1.32; 2.25 Episodes/ Person-Yr at Risk — p=0.04
Phase 1 N=2 Blood-Stage Plasmodium Vivax Cell Bank
Malaria
Primary: P. Vivax Blood Collection — 2 Participants
Phase 2 N=400 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine
Malaria, Falciparum
Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…
Phase 1 N=210 Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Year One — 39; 27; 19; 11 Participants
Phase 1 N=29 Trial to Evaluate CIS43LS in Healthy Adults
Malaria
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CIS43LS Product Administration — 4; 1; 5; 3 Participants
Phase 2 N=61 A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults
Malaria
Primary: Number of Subjects Reporting Plasmodium Falciparum (P. Falciparum) Parasitemia (Defined by a Positive Blood Slide) Following Sporozoite Challenge (in All Study Groups…
Phase 2 N=254 To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
Severe Malaria
Primary: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 Hours — 80.0; 93.0; 39.3 percentage of participants
Phase 2 N=1,737 Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 21; 17; 1; 0 Subjects